Here’s Why bluebird bio Shares Jumped Almost 12% Today
Shares of bluebird bio (NASDAQ: BLUE) jumped 11.9% today after the biotech presented data from a pair of clinical trials at the American Society of Hematology (ASH) annual meeting.
Bluebird presented data from the late-stage Northstar-3 clinical trial, showing that its LentiGlobin gene therapy could help patients with transfusion-dependent beta thalassemia who have harder-to-treat mutations called beta0 and IVS-I-110. Nine of 11 patients who had been followed for at least six months hadn't received an infusion to treat their disease in the three prior months.
The company also presented long-term follow-up results for earlier-stage clinical trials of LentiGlobin that showed the treatment was working in beta0. In the Northstar-2 study, for example, nine of 10 beta0 patients had achieved transfusion independence.
Source Fool.com
